Aurobindo Pharma liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

4.90×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.81×	1.81×	1.85×	1.95×	1.87×
1.15×	1.15×	1.13×	1.14×	1.13×
7,939	7,939	5,569	3,444	4,547
14,670	14,670	12,480	11,573	10,052

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,659.90

Aurobindo Pharma Ltd.

· Pharma & Health

₹ CrorePeersSUNPHARMA DRREDDY CIPLA FORTIS LUPIN ALKEM LAURUSLABS MANKINDMcap ₹96,407 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	4.90
Current Ratio	1.87	1.95	1.85	1.81	1.81
Quick Ratio	1.13	1.14	1.13	1.15	1.15
Cash, Equiv & ST Investments	4,547.3	3,444.1	5,569.0	7,938.6	7,938.6
Working Capital	10,051.9	11,572.8	12,480.1	14,669.7	14,669.7

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.